Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed unresectable solid tumor, including, but not limited to, the following:
• Lung cancer
• Breast cancer
• Head and neck cancer
• Bladder cancer
• Prostate cancer
• Must be suitable for treatment with single-agent docetaxel
• Hormone receptor status:
• Not specified
• PATIENT CHARACTERISTICS:
• Age:
• 18 and over
• Sex:
• Male or female
• Menopausal status:
• Not specified
• Performance status:
• CTC 0-2
• Life expectancy:
• Not specified
• Hematopoietic:
• Granulocyte count at least 1,500/mm\^3
• Platelet count at least 100,000/mm\^3
• Hepatic:
• Bilirubin less than upper limit of normal (ULN)
• Alkaline phosphatase less than 2.5 times ULN
• Renal:
• Creatinine no greater than 1.5 times ULN
• BUN no greater than 1.5 times ULN
• Other:
• Not pregnant or nursing
• Fertile patients must use effective contraception
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• No prior bone marrow transplantation
• No concurrent filgrastim (G-CSF) or sargramostim (GM-CSF)
• Chemotherapy:
• See Disease Characteristics
• At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)
• No prior docetaxel
• No more than 2 prior chemotherapy regimens
• No other concurrent chemotherapy
• Endocrine therapy:
• No concurrent hormonal agents except steroids for adrenal failure or hormones for non-disease-related conditions (e.g., insulin for diabetes)
• Radiotherapy:
• At least 3 weeks since prior radiotherapy
• No concurrent palliative radiotherapy
• Surgery:
• At least 4 weeks since prior major surgery
• Other:
• At least 6 months since prior Hypericum perforatum (St. John's Wort)
• At least 1 week since prior CYP3A enzyme inducers including:
• Phenobarbital
• Phenytoin
• Carbamazepine
• Lamotrigine
• Rifampin
• Rifabutin
• Isoniazid
• Sulfinpyrazone
• Pioglitazone
• Anti-HIV drugs such as efavirenz or nevirapine
• At least 1 week since prior CYP3A enzyme inhibitors including:
• Erythromycin
• Clarithromycin
• Azithromycin
• Roxithromycin
• Ketoconazole
• Fluconazole
• Itraconazole
• Metronidazole
• Chloramphenicol
• Ritonavir
• Saquinavir
• Indinavir
• Nelfinavir mesylate
• Delavirdine
• Amiodarone
• Cyclosporine
• Tacrolimus
• Sirolimus
• Nefazodone
• Fluvoxamine
• No concurrent CYP3A enzyme inducers
• No concurrent CYP3A enzyme inhibitors
• No ethanol (especially red wine), grape fruit juice, or seville orange juice (CYP3A enzyme inhibitor) within 3 days before or after receiving docetaxel